Drug Profile
Research programme: autoimmune disorder therapeutics
Alternative Names: AI-001Latest Information Update: 18 Sep 2023
Price :
$50
*
At a glance
- Originator University of British Columbia
- Developer BirchBioMed
- Class Cell therapies; Hydroxyquinolines; Small molecules
- Mechanism of Action Connective tissue growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alopecia; Psoriasis; Type 1 diabetes mellitus
Most Recent Events
- 18 Sep 2023 Autoimmune disorder therapeutics is still in preclinical trials for Alopecia, Psoriasis and Type-1 diabetes mellitus in Canada (BirchBioMed pipeline, September 2023)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Alopecia in Canada
- 28 Oct 2019 No recent reports of development identified for preclinical development in Psoriasis in Canada